Chicago Partners Investment Group LLC Grows Position in Illumina, Inc. $ILMN

Chicago Partners Investment Group LLC raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 85.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,200 shares of the life sciences company’s stock after buying an additional 2,398 shares during the period. Chicago Partners Investment Group LLC’s holdings in Illumina were worth $544,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC lifted its position in Illumina by 65.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 33,437 shares of the life sciences company’s stock valued at $2,653,000 after acquiring an additional 13,240 shares during the period. Janney Montgomery Scott LLC lifted its holdings in shares of Illumina by 109.0% during the first quarter. Janney Montgomery Scott LLC now owns 18,200 shares of the life sciences company’s stock valued at $1,444,000 after purchasing an additional 9,490 shares during the last quarter. State of Alaska Department of Revenue lifted its holdings in shares of Illumina by 2.5% during the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company’s stock valued at $1,469,000 after purchasing an additional 445 shares during the last quarter. Kentucky Retirement Systems purchased a new position in Illumina during the first quarter valued at $863,000. Finally, Kentucky Retirement Systems Insurance Trust Fund purchased a new position in Illumina during the first quarter valued at $368,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 1.7%

Shares of NASDAQ:ILMN opened at $97.23 on Thursday. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The stock has a market cap of $14.94 billion, a price-to-earnings ratio of 12.31, a PEG ratio of 2.44 and a beta of 1.40. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average price of $98.17 and a 200-day moving average price of $91.11.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.17. The firm had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm’s revenue was down 4.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Illumina in a report on Wednesday, October 8th. Morgan Stanley upped their price objective on Illumina from $100.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Monday, August 4th. Robert W. Baird increased their price objective on shares of Illumina from $84.00 to $105.00 and gave the stock a “neutral” rating in a research note on Monday, July 28th. Daiwa Capital Markets lowered shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective for the company. in a report on Tuesday, August 12th. Finally, Scotiabank cut Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 target price for the company. in a report on Friday, July 11th. Five research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $115.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.